Total Valuation
RELIEF THERAPEUTICS Holding has a market cap or net worth of $38.95M. The enterprise value is $16.26M.
Market Cap$38.95M
Enterprise Value$16.26M
Share Statistics
RELIEF THERAPEUTICS Holding has 159,102,450 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding159,102,450
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
RELIEF THERAPEUTICS Holding’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -34.28%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-34.28%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee271.52K
Profits Per Employee-552.23K
Employee Count31
Asset Turnover0.16
Inventory Turnover2.47
Valuation Ratios
The current PE Ratio of RELIEF THERAPEUTICS Holding is ―. RELIEF THERAPEUTICS Holding’s PEG ratio is 0.04.
PE Ratio―
PS Ratio6.27
PB Ratio1.44
Price to Fair Value1.44
Price to FCF-17.10
Price to Operating Cash Flow-11.00
PEG Ratio0.04
Income Statement
In the last 12 months, RELIEF THERAPEUTICS Holding had revenue of 8.42M and earned -17.12M in profits. Earnings per share was -1.36.
Revenue8.42M
Gross Profit5.84M
Operating Income-18.89M
Pretax Income-19.36M
Net Income-17.12M
EBITDA-16.73M
Earnings Per Share (EPS)-1.36
Cash Flow
In the last 12 months, operating cash flow was -3.40M and capital expenditures -26.00K, giving a free cash flow of -3.43M billion.
Operating Cash Flow-3.40M
Free Cash Flow-3.43M
Free Cash Flow per Share-0.02
Dividends & Yields
RELIEF THERAPEUTICS Holding pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.06
52-Week Price Change-90.29%
50-Day Moving Average0.43
200-Day Moving Average1.89
Relative Strength Index (RSI)28.80
Average Volume (3m)3.53K
Important Dates
RELIEF THERAPEUTICS Holding upcoming earnings date is Sep 17, 2026, Before Open (Confirmed).
Last Earnings DateApr 9, 2026
Next Earnings DateSep 17, 2026
Ex-Dividend Date―
Financial Position
RELIEF THERAPEUTICS Holding as a current ratio of 3.95, with Debt / Equity ratio of 5.82%
Current Ratio3.95
Quick Ratio3.74
Debt to Market Cap0.00
Net Debt to EBITDA0.77
Interest Coverage Ratio-273.70
Taxes
In the past 12 months, RELIEF THERAPEUTICS Holding has paid -2.24M in taxes.
Income Tax-2.24M
Effective Tax Rate0.12
Enterprise Valuation
RELIEF THERAPEUTICS Holding EV to EBITDA ratio is -2.38, with an EV/FCF ratio of -12.91.
EV to Sales4.74
EV to EBITDA-2.38
EV to Free Cash Flow-12.91
EV to Operating Cash Flow-13.67
Balance Sheet
RELIEF THERAPEUTICS Holding has $12.50M in cash and marketable securities with $1.90M in debt, giving a net cash position of $10.60M billion.
Cash & Marketable Securities$12.50M
Total Debt$1.90M
Net Cash$10.60M
Net Cash Per Share$0.07
Tangible Book Value Per Share$0.45
Margins
Gross margin is -29.03%, with operating margin of -224.37%, and net profit margin of -203.39%.
Gross Margin-29.03%
Operating Margin-224.37%
Pretax Margin-229.96%
Net Profit Margin-203.39%
EBITDA Margin-198.72%
EBIT Margin-229.14%
Analyst Forecast
The average price target for RELIEF THERAPEUTICS Holding is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―